AI in drug development

R&D

pharmaphorum podcast Episode 202a - Hilary Eaton, Profluent

Changing the drug development treatment paradigm: Hilary Eat...

Hilary Eaton, a rare disease advocate and chief business officer at Profluent, discusses AI-first protein design and accelerating biomedicine.

R&D

pharmaphorum podcast Episode 191a, Ben Sidders

Ben Sidders on integrating causality in AI for R&D success

Ben Sidders, chief scientific officer at Biorelate, discusses leveraging advanced data science methods to transform the focus and impact of R&D.

R&D

Post-hype, pre-value: The real AI-pharma shift starts now

The first era of AI in pharma was built on potential. This next era will be built on proof, reinforcing even greater potential.

Digital

pharmaphorum podcast Episode 176a - Andrew Stelzer, Unlearn.AI

AI in drug development: The real hurdle is implementation

Web editor Nicole Raleigh speaks with Andrew Stelzer, head of business development at Unlearn.AI, about effectively implementing AI.

R&D

Pharma trends and predictions for 2025: An incoming CEO’s pe...

Over the past two decades, I’ve observed significant shifts in the life sciences, pharmaceutical, and CDMO landscape.

Digital

pharmaphorum podcast Episode 161a - Isaac Bentwich

From science fiction to reality: AI in drug development

In today’s pharmaphorum podcast, web editor Nicole Raleigh speaks with Dr Isaac Bentwich, CEO and founder of Quris.AI.